Recombinant Der f1 Allergen Expression in Pichia pastoris
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for extracting dust mite allergens, such as Dermatophagoides farinae, involve cumbersome and costly processes, leading to impurities and variable composition, which can cause adverse reactions and misdiagnosis in treatments and diagnostics.
Innovation Solution
Optimization of the proDer f1 gene for expression in the Pichia pastoris system, including codon optimization and improved activation processes, results in higher expression levels and purification of recombinant Der f1 protein with similar biological activity to natural protein, using specific vectors and strains like pPIC3.5K and KM71.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If crude extract of dust mite allergens is used for treatment and diagnosis, then the process is simple, but the composition is variable and contains impurities that cause adverse reactions and misdiagnosis
Solution Approach 1:
The patent extracts only the specific allergenic components (Der f1 and Der f2 proteins) from the complex dust mite mixture through recombinant expression systems. This selective extraction eliminates non-allergenic impurities while maintaining the therapeutic allergens, resolving the contradiction between simple extraction and composition consistency.
Solution Approach 2:
The patent changes the production parameters from traditional extraction methods to recombinant DNA technology parameters. By optimizing expression conditions, purification protocols, and protein folding parameters in the recombinant system, consistent and pure allergen products are achieved, eliminating batch-to-batch variability inherent in crude extracts.
2Quantity of substance
If crude extract of dust mite allergens is used, then the production cost is low, but the process is cumbersome and time-consuming
Solution Approach 1:
The patent performs preliminary action by pre-expressing the allergen proteins in recombinant host cells before clinical use is needed. The recombinant Der f1 and Der f2 proteins are produced in advance through optimized expression systems, eliminating the need for time-consuming extraction and purification processes when the allergen is actually needed for treatment or diagnosis.
Solution Approach 2:
The patent creates copies of the natural allergen proteins through recombinant DNA technology. Instead of extracting proteins from actual dust mites (which requires time and resources), the patent synthesizes identical protein copies in bacterial or mammalian expression systems, dramatically reducing production time while maintaining allergenic activity.
3Quantity of substance
If crude extract of dust mite allergens is used, then the initial production cost is low, but the purification cost and complexity increase due to impurities and contamination
Solution Approach 1:
The patent extracts only the specific allergenic components (Der f1 and Der f2 proteins) from the complex dust mite mixture through recombinant expression systems. This selective extraction eliminates non-allergenic impurities while maintaining the therapeutic allergens, resolving the contradiction between simple extraction and composition consistency.
Solution Approach 2:
The patent introduces recombinant host cells as an intermediary system between the allergen source and the final product. These host cells (bacterial or mammalian) serve as factories that produce pure allergen proteins directly, eliminating the need for complex purification steps required when starting from crude dust mite extracts.
4Duration of action of stationary object
If crude extract of dust mite allergens is used for long-term treatment, then the treatment duration is extended, but adverse reactions such as local reactions and systemic reactions increase
Solution Approach 1:
The patent changes the purity parameter of the allergen from crude extract to highly purified recombinant protein. This parameter change eliminates contaminants that cause adverse reactions, allowing long-term treatment to proceed safely. The recombinant Der f1 and Der f2 proteins maintain full allergenic activity while being free from toxic impurities.
5Ease of operation
If crude extract of dust mite allergens is used for diagnosis, then the diagnostic process is simple, but the measurement precision is poor due to inability to determine specific component responses
Solution Approach 1:
The patent segments the complex dust mite allergen mixture into distinct, purified components (Der f1 and Der f2 proteins). Each recombinant allergen can be tested separately in diagnostic assays, allowing precise determination of which specific component triggers the patient's allergic response. This segmentation maintains diagnostic simplicity while dramatically improving measurement precision.
Data Source
AI summary
Provided are an optimized proDer f1 gene, a proDer f1 protein encoded thereby, a vector comprising said gene, and a Pichia pastoris strain. Also provided are an expression method and a purification method of the proDer f1 protein.